What question did this study set out to answer?

The study aims to explore the role of MEF2A in promoting drug resistance and cancer progression in acute myeloid leukemia.

March 28, 2026Biology Direct0 citationsOpen Access

MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia

XMXi MingTongji Hospital WLWanying LiuTongji Hospital JWJiaying WuTongji Hospital

Key Points

The study aims to explore the role of MEF2A in promoting drug resistance and cancer progression in acute myeloid leukemia.
Investigated the relationship between MEF2A and ZDHHC20 expression levels.
Analyzed the activation of the NF-κB pathway in response to MEF2A.
Evaluated the impact of targeting the MEF2A/ZDHHC20 axis on drug resistance.
MEF2A enhances ZDHHC20 expression, leading to NF-κB pathway activation.
Doxorubicin sensitivity is reduced in models where MEF2A is active.
Targeting MEF2A/ZDHHC20 shows promise for overcoming drug resistance.

Abstract

MEF2A promoted AML progression and DOX resistance by transcriptionally upregulating ZDHHC20, thereby activating the NF-κB pathway. Targeting the MEF2A/ZDHHC20 axis represents a promising therapeutic strategy to overcome chemoresistance and improve clinical outcomes in AML patients.

Demander à l'IA

Bookmark

View Full Paper